ArticleHepatology communications2026
ROTEM-detected hypocoagulability is associated with major non-portal hypertensive bleeding in cirrhosis.
Article in Hepatology communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with acute-on-chronic liver failure (ACLF) display preserved thrombin generation (TG) but hypocoagulable profiles on rotational thromboelastometry (ROTEM). The relationship with non-portal hypertensive (NPH) bleeding is unclear. The primary aim was to assess hemostatic alterations across the clinical spectrum of cirrhosis, including stable cirrhosis (SC), stable decompensation (SD), acute decompensation (AD), and ACLF, and their association with NPH bleeding.
methodsIn this prospective cohort and nested case-control study, 215 cirrhotic patients (SC=70; SD=50; AD=53; ACLF=42) underwent coagulation testing, including conventional coagulation tests, coagulation factors and inhibitors, ROTEM and TG [±thrombomodulin (TM)].
resultsACLF patients showed a higher prevalence of hypocoagulable ROTEM profiles (≥5 abnormal parameters) compared with SC, SD, and AD (23.8% vs. 0% in SC and 4% in SD, p<0.05; 13.2% in AD, p=0.33), while TG potential with TM was comparable across groups. Major NPH bleeding (spontaneous and post-procedural) occurred in 8.4% of patients, with a prevalence of 17% in AD and 21.4% in ACLF. Patients with NPH bleeding more frequently exhibited a hypocoagulable ROTEM profile compared with those without bleeding (44.4% vs. 5.1%, p<0.001). Using LASSO-penalized logistic regression, a hypocoagulable ROTEM profile showed the strongest independent association with NPH bleeding (λ₁se model: OR 1.48, 95% CI 1.17-2.06; cross-validated AUC 0.75). The λ_min model showed incrementally higher discriminative performance (cross-validated AUC 0.79) and additionally included MELD-Na score (confounder), bacterial infection, fibrinogen, and platelet count, but a hypocoagulable ROTEM profile also showed the strongest association (OR 2.02, 95% CI 1.30-3.15), comparable to the results in the more parsimonious λ₁se model.
conclusionsROTEM-detected hypocoagulability was independently associated with major NPH bleeding in cirrhosis. Its clinical implications warrant further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.